Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Tuesday, October 27, 2026

Back to today

From X

@StableBread 4 clicks

Fajasy on X

“We are in active discussions with some of the largest GPU consumers in the world, with requirements ranging from 10,000-50,000 GPUs. Those discussions are not yet contracts, and we will announce them only when they are.” That’s what Boost Run $BRUN CEO Andrew Karos said on the Q2 call. None of my bear, base, or bull cases considers a contract with one of those buyers. At Thinking Machines’ $3.59/GPU-hour, a single 10,000-GPU contract would bring in $314.5M/year, 78.6% of the $400M 2026 target. Karos also said $BRUN is procuring another $4-5B of computing hardware from multiple manufacturers. If all of it were rented out on three-year contracts at 1.4x TCV-to-capex (contract value divided by what the GPUs cost), the hardware would bring in $1.9-2.3B/year, 4.7-5.8x the 2026 target. But if lessors fund 79.5% of the purchases, as they did in H1 2026, $BRUN would also take on $3.2-4.0B of new lease debt. So how $BRUN finances the procurement decides how much of the $1.9-2.3B reaches shareholders.
@BrokenMoats

Broken Moats on X

Have to give credit the squeeze in software is remarkable, they didn't even stop buying them with semis up n the open. Stocks like $MNDY flying 8% yesterday, $APPN up over 8% today (30% in a week after Barclays remained underweight with a price target roughly 40% current) after their closest comp reported very disappointing earnings and warned of demand and a restructuring.....truly incredible. Starting to give the $GRAL/ $TXG/ $TWST type manic move from a few weeks ago
@BlueDuckCap 2 clicks

BDC on X

This is a big deal. Strategic acquisition and verticalization of value based oncology care continues leaving $STLN as uniquely scare and thus strategic from here. AONC has no speciality pharma piece and yet is getting bought for 17x gross profit. $STLN is the last multi state actually-acquirable platform. What's left outside STLN is subscale: Utah Cancer Specialists (~40), Cancer Care Northwest (~30), Western Michigan (~30), plus Levitate Ridge's early West Coast platform. There are 2,000+ oncology groups in the US, but almost none with multi-state density. Cardinal has the smallest footprint and no VBC capability, which makes it the most plausible remaining strategic — followed by a payer (Carelon, Optum) or PE. Key point is that we believe $STLN is the much better asset and putting the 17x gross profit acquisition multiple on runrate 2027 estimates gets us ~$25 stock. Not advice.
@StableBread 3 clicks

Fajasy on X

How much of the $400M of ARR that Boost Run $BRUN is targeting by December 31 is already signed? Five of its seven contracts with disclosed terms can count toward the $400M target, since the July order and Cohere, $160.7M/year combined, don’t start until 2027. If Thinking Machines Lab’s GPUs are fully running by December 31 and the June order starts on November 30, the five cover $300.6M (75.1%) of the target, leaving $99.4M for contracts without disclosed terms. For comparison, the Q2 deck’s deployment schedule had $0.4B of the then-$1.9B of TCV in production by the end of Q2, with all of it live by Q1 2027. From there, the deck shows another $0.4B of TCV going into production in Q3 and another $0.4B in Q4, a straight line to $1.2B by year-end that management calls consistent with the $400M+ ARR target. The deck’s footnote says the Q3 figure is a management estimate “interpolated from disclosed metrics,” so the actual climb will likely be lumpier, with the June order alone starting November 30. Cohere’s racks start in Q2 2027, right after the deck’s schedule ends, so even without a new contract, $BRUN has signed deployments lined up through mid-2027. $BRUN’s last ARR figure was $145M as of June 30, from the Q2 call, so the Q3 report (expected in mid-November) will be the first check on H2 2026. A straight-line climb from $145M (as of June 30) to $400M by December 31 would mean $136.3M of H2 2026 revenue, in line with the $127.9-137.9M needed to hit the $170-180M of 2026 revenue its October 8 prospectus amendment still estimates. By quarter, that climb works out to $52.2M of revenue in Q3 and $84.1M in Q4, up from $31.1M in Q2. In other words, the year-end target is mostly contracted, and the risk is getting the GPUs bought, financed, and running by December 31.

Investor Letters

All letters

Are Neoclouds Dead?

Neoclouds face tighter debt financing as AI infrastructure capex outruns cash flow, leaving cash-burning GPU providers more exposed than…

NBIS $42B
Daniel Romero 9 clicks

Reddit: Deep Dive Analysis

Reddit generated $805 million in Q2 2026 revenue, 95% from ads, but slowing Google search referrals expose AI-driven traffic and…

RDDT $18B
Hated Moats 6 clicks

Qualcomm Inc. (QCOM)

Qualcomm supplies chips for on-device AI agents and data center inference, with Meta and AWS agreements expanding its role across both…

QCOM $195B
SixSigmaCapital: Navigating the Financial Markets 5 clicks
WULF · long

Terawulf INC

TeraWulf is shifting from bitcoin mining toward data centers, seeking a higher-quality and more defensive business model.

WULF $5.4B
Value Investors Club

The Data Center Bridge

Small- and mid-cap data center stocks trade as one despite sharply different funding bridges: 12 of 15 cover fixed costs on signed…

IREN $11BFRMI $1.9B
CV's Substack 16 clicks

Amkor Q3 FY12/26 Earnings Review

Amkor's Q3 sales were flat at $1.991 billion as computing and automotive/industrial growth offset a 27% communications decline; Q4 sales…

AMKR $10B
Cestrian Capital Research 4 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 67 of 269

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.